Shares of Oxford Immunotec Global PLC (NASDAQ:OXFD) have received an average recommendation of “Hold” from the seven analysts that are presently covering the stock, MarketBeat Ratings reports. Three investment analysts have rated the stock with a sell recommendation and four have assigned a buy recommendation to the company. The average twelve-month price target among analysts that have covered the stock in the last year is $19.75.

OXFD has been the subject of several research analyst reports. Cowen and Company reaffirmed a “buy” rating and set a $22.00 price target on shares of Oxford Immunotec Global PLC in a research note on Thursday, August 3rd. BTIG Research initiated coverage on Oxford Immunotec Global PLC in a research note on Thursday, September 28th. They set a “buy” rating and a $21.00 price target for the company. Zacks Investment Research raised Oxford Immunotec Global PLC from a “sell” rating to a “hold” rating in a research note on Wednesday, October 4th. ValuEngine lowered Oxford Immunotec Global PLC from a “hold” rating to a “sell” rating in a research note on Tuesday, October 31st. Finally, Robert W. Baird reissued a “buy” rating and issued a $20.00 target price on shares of Oxford Immunotec Global PLC in a research note on Wednesday, November 1st.

Shares of Oxford Immunotec Global PLC (OXFD) opened at $12.94 on Friday. The company has a debt-to-equity ratio of 0.38, a current ratio of 4.72 and a quick ratio of 4.30. Oxford Immunotec Global PLC has a 52 week low of $12.19 and a 52 week high of $19.51.

In related news, CEO Peter Wrighton-Smith sold 55,000 shares of the business’s stock in a transaction dated Monday, October 2nd. The stock was sold at an average price of $16.78, for a total transaction of $922,900.00. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Richard A. Sandberg sold 3,000 shares of the business’s stock in a transaction dated Wednesday, November 1st. The shares were sold at an average price of $13.35, for a total value of $40,050.00. Following the transaction, the director now owns 17,778 shares in the company, valued at approximately $237,336.30. The disclosure for this sale can be found here. In the last three months, insiders sold 70,739 shares of company stock valued at $1,167,597. 8.11% of the stock is currently owned by corporate insiders.

A number of large investors have recently made changes to their positions in OXFD. Renaissance Technologies LLC increased its holdings in Oxford Immunotec Global PLC by 97.8% during the 1st quarter. Renaissance Technologies LLC now owns 363,300 shares of the company’s stock valued at $5,628,000 after purchasing an additional 179,600 shares during the period. Columbus Circle Investors purchased a new position in shares of Oxford Immunotec Global PLC during the 3rd quarter worth approximately $2,640,000. Redmile Group LLC grew its holdings in shares of Oxford Immunotec Global PLC by 7.5% during the 2nd quarter. Redmile Group LLC now owns 2,155,949 shares of the company’s stock worth $36,263,000 after acquiring an additional 151,100 shares during the period. Wasatch Advisors Inc. grew its holdings in shares of Oxford Immunotec Global PLC by 35.5% during the 3rd quarter. Wasatch Advisors Inc. now owns 574,174 shares of the company’s stock worth $9,646,000 after acquiring an additional 150,343 shares during the period. Finally, EAM Investors LLC purchased a new position in shares of Oxford Immunotec Global PLC during the 3rd quarter worth approximately $2,023,000. Institutional investors own 78.77% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This piece of content was posted by Watch List News and is the property of of Watch List News. If you are viewing this piece of content on another website, it was illegally copied and republished in violation of international copyright legislation. The correct version of this piece of content can be accessed at https://www.watchlistnews.com/oxford-immunotec-global-plc-oxfd-given-average-recommendation-of-hold-by-brokerages/1694551.html.

Oxford Immunotec Global PLC Company Profile

Oxford Immunotec Global PLC is a diagnostics company. The Company is focused on developing and commercializing tests for under-served immune-regulated conditions. The Company’s product lines and development activities principally focus on four areas: infectious diseases, transplantation, autoimmune and inflammatory disease and immune-oncology.

Receive News & Ratings for Oxford Immunotec Global PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford Immunotec Global PLC and related companies with Analyst Ratings Network's FREE daily email newsletter.